Key result
Liraglutide alone or combined with insulin detemir did not alter myocardial glucose uptake compared with insulin detemir alone in patients with type 2 diabetes.
Why the study?
Does liraglutide alone or combined with insulin detemir alter myocardial fuel selection compared with insulin detemir alone in patients with type 2 diabetes?
RCT
Does liraglutide alone or combined with insulin detemir alter myocardial fuel selection compared with insulin detemir alone in patients with type 2 diabetes?
Liraglutide at clinical doses does not significantly alter myocardial fuel metabolism compared to insulin in patients with type 2 diabetes, suggesting its cardiovascular benefits are not mediated by large changes in myocardial fuel selection.
Answers are grounded in this paper and cite their sources.
Does not alter diabetes management for myocardial glucose uptake; leaves open broader cardiac metabolic effects in larger trials.
Context: It is unclear if effects of glucagon-like peptide-1 (GLP-1) and clinically available GLP-1 agonists on the heart occur at clinical doses in humans, possibly contributing to reduced cardiovascular disease risk. Objective: To determine whether liraglutide, at clinical dosing, augments myocardial glucose uptake (MGU) alone or combined with insulin compared with insulin alone in metformin-treated type 2 diabetes mellitus (T2D). Design: In a randomized clinical trial of patients with T2D treated with metformin plus oral agents or basal insulin, myocardial fuel use was compared after 3 months of treatment with insulin detemir, liraglutide, or combination detemir plus liraglutide added to background metformin. Main Outcome Measures: Myocardial blood flow (MBF), fuel selection, and rates of fuel use were evaluated using positron emission tomography, powered to demonstrate large effects. Results: MBF was greater in the insulin-treated groups [median (25th, 75th percentile): detemir, 0.64 mL/g/min (0.50, 0.69); liraglutide, 0.52 mL/g/min (0.46, 0.58); detemir plus liraglutide, 0.75 mL/g/min (0.55, 0.77); P = 0.035 comparing three groups, P = 0.01 comparing detemir groups to liraglutide alone]. There were no evident differences among groups in MGU [detemir, 0.040 µmol/g/min (0.013, 0.049); liraglutide, 0.055 µmol/g/min (0.019, 0.105); detemir plus liraglutide, 0.037 µmol/g/min (0.009, 0.046); P = 0.68 comparing three groups]. There were no treatment-group differences in measures of myocardial fatty acid uptake or handling, and no differences in total oxidation rate. Conclusion: These observations argue against large effects of GLP-1 agonists on myocardial fuel metabolism as mediators of beneficial treatment effects on myocardial function and ischemia protection.
No takes yet. Share an insight, caveat, or question.
Mather et al. (2018) conducted an RCT in Type 2 diabetes mellitus. Liraglutide alone or combined with insulin detemir vs. Insulin detemir alone was evaluated on Myocardial glucose uptake (MGU) (p=0.68). Liraglutide alone or combined with insulin detemir did not alter myocardial glucose uptake compared with insulin detemir alone in patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: